Malnutrition is one of the major problems for children with cancer.' Previous studies have shown that at diagnosis these patients are adequately nourished, suggesting that the cause of the malnutrition is predominantly iatrogenic.2 Though the link between nutritional status and clinical outcome remains incompletely defined, impaired immune function associated with the therapeutic management in combination with malnutrition, either additively or synergistically, may increase the susceptibility of the child to infection.3 This in turn may influence clinical outcome.
In the long term poor nutrition will also limit growth and development. Growth deficits have been recorded in a large group with a diagnosis of acute lymphoblastic leukaemia but it was unclear whether the deficit was attributable to the disease process itself, infection, or the therapeutic management of the patient. 4 Atterition has been principally directed towards studying the changes in energy intake and expenditure during the initial period of intensive treatment after diagnosis.5-7 Energy requirements may be raised as a result of cachectic side effects of treatment or infection. The limited number of published studies in children with recently diagnosed cancer have suggested that energy expenditure at rest may indeed be greater than predicted. 7 However, in two studies this appeared to be normalised within seven days of initial treatment. 5 6 In the study conducted by Merritt and colleagues basal metabolic rate (BMR) was raised over a period of 30 days.7 Although all these studies appear to indicate some degree of raised metabolism at diagnosis of cancer and during the first month of treatment, energy requirements during the longer period of maintenance chemotherapy that follows remain unknown.
The purpose of this study was to examine the effect of maintenance chemotherapy alone on the energy intake and BMR of patients without active disease. Measurements of energy intake and BMR were carried out in a group of patients receiving continuous chemotherapy, after the attainment of remission from acute lymphoblastic leukaemia or solid tumours. Their results were compared with those from normal healthy children matched for age and gender.
Subjects and methods

PATIENTS
Twenty six children (aged 5 to 16 years) receiving chemotherapy took part in the study. Sixteen BMR was expressed in kJ/day, corrected for difference in fat free mass, and as a percentage of that predicted on the basis of age, gender, weight, and height. 6 Height was determined using a Holtain stadiometer. Weight was determined by standing balance scales. Standard deviation (SD) scores were determined for height. figure) . There were no apparent differences in energy intake:BMR ratio between the two treatment groups.
Discussion
Parents of children receiving cytotoxic drugs often express concern that their child may not be eating adequately to satisfy their body's requirements for energy and nutrients. Anorexia and weight loss are prevalent in cancer patients, and those children who have been receiving treatment for long periods of time are more likely to be malnourished.23 Furthermore several studies which followed up children in long term remission from cancer demonstrated a tendency toward poor growth.4 [24] [25] [26] A limitation in growth has to relate to an imbalance between energy intake and energy expenditure and must include consideration of three factors: poor dietary intake, increased faecal losses, and the nature and magnitude of metabolic demand. Deficiencies of specific micronutrients that may also limit growth once energy needs are satisfied should not be overlooked.
Two studies have measured energy expenditure at rest in children with cancer. Kien and Camitta report a limited series of observations in eight children with newly diagnosed acute lymphocytic leukaemia.5 BMR was measured by indirect calorimetry for a five minute period during which time some of the children slept. The results were expressed as a percentage of published values for normal children and revealed that the mean increase in BMR was 50% (range 16-166%) above normal. This study is frequently cited as evidence of a raised metabolic demand in children with cancer. It should be noted that apart from potential errors associated with such a brief period of measurement, no attempts were made to compare these results with the BMR determined in a control group. It is also not possible to determine whether these measurements were made before or after treatment was initiated.
In a subsequent study by Stallings et al greater attention was paid to technical detail and measurements of BMR were made in nine children with newly diagnosed acute lymphoblastic leukaemia before and during the first two weeks of chemotherapy.6 Energy expenditure at rest was determined in the patients who were subdivided into two groups with differing tumour burden. They found that only the three patients with a high white cell count at diagnosis exhibited a BMR that was 13-45% greater than that predicted from age, sex, and size. The remaining six patients with low tumour burden exhibited BMR values comparable with that predicted from age, sex, and size. The raised BMR of the high tumour burden group rapidly returned to normal with treatment. While chemotherapy treatment per se did not appear to raise BMR, changes in substrate utilisation were observed that appeared to be more persistent. They noted that as most chemotherapy programmes for children with acute lymphoblastic leukaemia last up to three years, longitudinal follow up of intermediary metabolism is important to determine whether there is a profound and permanent effect on metabolism, growth, and development.
In this present study energy intakes and BMRs were determined in children receiving ongoing chemotherapy while otherwise well and having no evidence of active disease. Both patients and healthy controls appeared to consume equivalent amounts of energy with their mean values between 13-15% less than their recommended daily amount for energy. Both groups exhibited values for BMR that were comparable, whether expressed in standard units, per kg of fat free mass, or as a percentage of that predicted from age, sex, height, and weight.
The mean ratio of energy intake to BMR (BMR factor) was the same for both groups, 1-59. There is very little published information on energy intake:BMR ratios in children of this age group against which our results may be compared. This value is slightly lower than the desirable energy allowance for populations expressed as a ratio of BMR estimated from patterns of physical activity for this age group (boys 1-76, girls 1-65).27 The range of BMR factors of the patients was large (096-2 73) and appeared to be greater than that reported for the control group (1- 232-46; see figure) .
Seven of the children receiving chemotherapy reported energy intakes that were less than or only slightly greater than their BMR values. These patients were not the ones who fell into the category of being stunted or wasted. Those patients already showing signs of poor growth may have experienced energy deprivation in the past and their metabolism adapted to the reduced intake. There would be no method of measuring whether this was during early childhood, at the time of the initial disease, or during previous treatment.
Though this may be interpreted as evidence that the food intake of these children was insufficient, it is important to recognise that this may also reflect the under-reporting of food intake.28 Considerable efforts were taken in this study to limit the possibility of inaccurate reporting offood intake. In addition the problem of undereating during the period of measurement should not be ruled out.29 There was no evidence of energy imbalance, as indicated by measurements of weight, between the start and end of the diary recording. It was not possible to make measurements of habitual physical activity during this study.
This study represents the first occasion in which energy intakes and basal metabolic rates have been determined beyond induction chemotherapy. We found that in the week before chemotherapy the dietary intake of energy and the expenditure of energy at rest of a group of patients receiving chemotherapy gave little evidence to suggest that undernutrition was a problem for these patients. However, the sample size was relatively small, the group fairly heterogeneous and possibly not representative of their respective patient populations. For example the patients with acute lymphoblastic leukaemia were older than a typical patient population. If there is a long term energy deficit leading to poor growth in some children with acute lymphoblastic leukaemia, further studies need to investigate these components of energy balance during other stages of the cycle of treatment and with a younger homogeneous patient group.
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